Contribute Try STAT+ Today

Good morning everyone, hope you’re savoring the fresh start that comes with the beginning of the week. This is Rachel Cohrs sitting in today. Our morning cup of stimulation comes in the form of a steaming mug of English breakfast tea, as your author isn’t much of a coffee drinker — hopefully Ed will forgive the departure from canon. Here are a few items to help you catch up this Monday, and as always, stay in touch. …

Pfizer (PFE) will buy cancer-drug developer Trillium Therapeutics (TRIL) in a deal that values the company at $2.26 billion, Reuters reports. Trillium develops drugs that boost patients’ immune systems to fight off cancer cells, and its two leading candidates focus on blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment